Elekta stock gained 3.34 percent on September 28 as radiotherapy expanded

Published on 09/29/2026 at 08:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock was last at SEK 52.55 on Nasdaq Stockholm on September 28, 2026, with market value of SEK 19.3 billion. UBS kept a SEK 41.00 target on September 8.

Flatlay mit Aktienzertifikat, ISIN-Karte und medizinischen Utensilien auf weißem Untergrund — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte SE0000163628 zeigt Investment-Utensilien passend zur Branche von Elekta AB, Illustration mit AI erstellt.

Elekta stock (ISIN SE0000163628) was last at SEK 52.55 on Nasdaq Stockholm on September 28, 2026, up 3.34 percent on the session. The move came as the Swedish medical technology company presented new adaptive radiotherapy capabilities and fresh clinical data at ASTRO 2026.

Adaptive portfolio expands at ASTRO

According to Elekta on September 27, 2026, the company added online adaptive capability for Elekta Harmony and introduced real-time adaptive planning for prostate brachytherapy through Prostate Guideway. The expanded portfolio also covers Elekta Unity, Elekta Evo and Leksell Gamma Knife Esprit, linking CT-guided, MR-guided and radiosurgery workflows through Elekta ONE software.

The commercial significance is practical rather than purely technical. Elekta says Harmony is designed for everyday treatment throughput, while the new workflows allow clinicians to adapt plans to patient anatomy during treatment. Prostate Guideway remains pre-commercial and awaits US FDA 510(k) clearance and EU CE marking, according to the same September 27 release.

Clinical data add a second catalyst

A separate Elekta release dated September 28, 2026 described a study of 123 patients treated with Elekta Unity between May 2020 and December 2024. Overall survival was 37.4 percent at two years and 26.3 percent at three years, while 76.8 percent of patients remained free from local progression at both points.

For the operating picture, Elekta's investor-relations page identifies the most recent report as Q1 FY2026/27, covering May through July 2026. The company reported a 2 percent decline in group net sales at constant exchange rates, making adoption and margin execution important tests for the product expansion.

Analyst caution meets stock recovery

According to MarketScreener on September 8, 2026, UBS retained its sell recommendation and a SEK 41.00 price target after the first quarter. The target was 21.02 percent below the September 28 price, highlighting the gap between product momentum and concerns about China, US competition and cost inflation.

Elekta's September 28 price stood 21.22 percent below its 52-week high of SEK 66.70 and above its low of SEK 41.86. Volume reached 2,429,963 shares, while the market capitalization was SEK 19.3 billion.

Next report is scheduled for November

Elekta's investor-relations calendar lists the Q2 report for November 25, 2026. The next reporting date puts the new product rollout and the latest clinical evidence against a clearly defined financial checkpoint.